EuroSIDA Cohort IX
In January 2012 enrolment forms were sent out to the EuroSIDA centres that will enroll new patients into EuroSIDA Cohort IX. Deadline for returning the completed enrolment forms to CHIP is 1st May 2012. If you have problems meeting this deadline, please contact Jorunn at jtv@cphiv.dk

Ethical Approval
If your EuroSIDA centre has obtained a new Ethical Approval for your participation in the EuroSIDA study, please send a copy of the approval to Jorunn at  jtv@cphiv.dk or fax it to +45 35 45 57 58.

Plasma samples
Plasma samples are collected every 6th month as mandatory part of participating in the EuroSIDA study. These plasma samples are increasingly important for the study. If your centre is not collecting these plasma samples, please see the attached document about plasma samples in EuroSIDA or contact Annette at ahf@cphiv.dk for further instructions on the procedures of colleting the samples. If your centre has plasma samples ready to be shipped to the Coordinating Centre, please contact Annette. Your centre is reimbursed 5 Euro per plasma sample.

Latest Publications

The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.  A Mocroft et al, for EuroSIDA in EuroCoord (Antiviral Therapy, in press)

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes : A cohort study. D Costagliola, R Lodwick, B Ledergerber, C Torti, A van Sighem, D Podzamcer, A Mocroft, et al. The Pursuing Later Treatment Option II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group. Lancet Infect Dis. 2012 Feb;12(2):119-127. Epub ahead of print 2011 Oct 7

EuroSIDA at 16th IWHOD-International Workshop on HIV Observational Databases in Athens, Greece

Risk factors for advanced CKD and End stage renal disease in HIV positive patients, L Ryom et al (oral)

Temporal changes and regional differences in the uptake of HCV therapy, D Grint et al (oral)

Estimation of percentage of HIV-infected people with limited antiretroviral drug options in a closed observational setting over the period 2006-2010 and beyond, A Cozzi-Lepri et al (poster)

Predicting the extent of drug resistance using previous history of virological failure: classical and Bayesian approaches, ACozzi-Lepri et al (poster)

Total EuroSIDA publications as of March 2012: 161